Management of peritoneal dialysis
*Mycobacterium abscessus* exit-site infection: A case report and literature review

Korey Bartolomeo, Mohamed Hassanein and Tushar J Vachharajani

Abstract
Peritoneal dialysis associated infections are common and associated with high morbidity and mortality, if not treated in a timely manner. *Mycobacterium abscessus* is an uncommon pathogen in peritoneal dialysis associated infections, but is resistant to standard antimicrobial therapies used. Here we present a case of a 56-year-old male with end stage kidney disease on peritoneal dialysis for 7 years who developed a *Mycobacterium abscessus* exit-site infection. Peritonitis and peritoneal dialysis catheter tunneled line infections were ruled out and he was treated with linezolid, amikacin, and azithromycin. He required peritoneal dialysis catheter removal and hemodialysis conversion. Antibiotics were de-escalated based on *erm* inducibility and antibiotic sensitivities. Linezolid and amikacin were continued for approximately 7 total weeks, with complete resolution of the infection. Further research is needed to refine challenges in the management of *Mycobacterium abscessus* exit-site infections, including risk factors for development of *Mycobacterium abscessus*, optimal selection of empiric antibiotic therapies, duration of antibiotics, and peritoneal dialysis catheter re-insertion timing.

Keywords
Peritonitis, exit site infection, peritoneal dialysis, *M. abscessus*

Introduction
Peritoneal dialysis (PD) is a commonly employed modality for kidney replacement therapy both worldwide and in the United States. PD-associated infections include peritonitis, tunnel infections, and exit-site infections (ESI). ESI have a strong association with failure of PD ultrafiltration and solute clearance, increased hospitalizations, and high mortality.1,2 Given this, empiric antibiotic therapies targeting the most common gram-negative and gram-positive bacteria, are used to treat suspected ESI.3

Nontuberculous mycobacteria are acid-fast bacilli that include *Mycobacterium abscessus* complex. *M. abscessus* are ubiquitously found in the environment, characterized by rapid growth and intrinsic resistance to common antibiotics.4 There is a growing body of literature of *M. abscessus* involvement in PD-associated infections with little consensus in regards to antibiotic choice, duration of treatment, and catheter removal timing.5,6 Publications on *M. abscessus* involved ESI in adults are more limited, with only 2 case reports from the United States.7,8 More recently, case reports on *M. abscessus* ESI have described differing management principles and high rates of complications, highlighting a large knowledge gap and lack of guiding evidence in this disease.8–10 Here we report a case of *M. abscessus* ESI and discuss current evidence supporting management of this difficult diagnosis.
Case Report

A 56-year-old male emigrated from the Philippines 27 years ago reported purulent drainage from his PD exit site to his PD nurse in the setting of poor appetite. He has had end stage kidney disease from IgA nephropathy requiring PD for 7 years, and recurrent bacterial peritonitis from coagulase negative Staphylococcus (three times prior). His medical history was additionally notable for a Bosniak class IV right renal cyst, hypertension, obsessive compulsive disorder, and partially treated latent Mycobacterium tuberculosis 2 years prior to presentation. He was also briefly converted to hemodialysis after requiring PD catheter removal and reinsertion for Staphylococcus peritonitis for 2 months, 1 year prior to his current presentation. His PD regimen at the time of the noted drainage was continuous cycling PD with 3 cycles, 150 min for each cycle, and 2.8 L bags of 1.5% dextrose solution, followed by a last bag and mid-day exchange for additional solute clearance.

His clinical course is summarized in Figure 1. Wound swabs were taken of the exit-site discharge, hypertonic saline soaks were started and he was instructed to follow up with infectious disease clinic for further management. He developed worsening nausea, vomiting, and dizziness over the next 10 days and was instructed to present to the emergency department. His initial wound swabs were identified as Mycobacterium abscessus on matrix assisted laser desorption ionization-time of flight mass spectrometry 5 days after the cultures were obtained. His initial physical examination was without abdominal tenderness or active PD exit-site drainage and his vital signs were within normal limits. His admission labs were notable for a WBC of 10.4 × 10⁶ cells/L (normal 3.7 × 10⁶–11.0 × 10⁶ cells/L) only. A PD fluid sample was obtained showing clear fluid and a total nucleated cell count of 2 cells/µL with negative gram stain and culture. Computed tomography imaging of the abdomen was negative for abscess or fluid collection.

He was continued on PD for dialysis until the catheter was removed on hospital day 3. He was transitioned to hemodialysis via a previously placed left upper extremity brachiocephalic fistula. Azithromycin 250 mg daily, linezolid 600 mg daily, and amikacin 350 mg after hemodialysis were started on hospital day 5 while genetic susceptibility tests were pending. He was discharged on hospitalization day 13 on these antibiotics, 22 days after the initial wound culture was obtained.

He was re-hospitalized 2 weeks later with community acquired pneumonia, requiring addition of piperacillin-tazobactam and transition to amoxicillin-clavulanate for 5 days. Azithromycin was also discontinued after erm inducibility was detected in his initial M. abscessus wound swab and wound swab antibiotic sensitivities were finalized (Table 1). He had one additional hospitalization for worsening dyspnea and a negative cardiac work-up for ischemia. He completed seven total weeks of linezolid and amikacin, with both discontinued after he had persistence of vestibular symptoms, including dizziness. He has since remained asymptomatic with a healed exit site wound. He has remained on hemodialysis since removal of the PD catheter.

Discussion

M. abscessus PD ESI are likely underdiagnosed in clinical practice and underrepresented in published literature. To
our knowledge this is only the third *M. abscessus* PD ESI acquired in the United States in adults, and the first without diabetes or active immunosuppression. Management of diagnosed *M. abscessus* ESI is challenging because of a lack of guidelines on initiation and duration of antibiotics, as well as intrinsic resistance of the pathogen. Rapid growth of *M. abscessus* allows for identification of the pathogen by day 5 after cultures taken, identified in our case based on MALDI-TOF mass spectrometry.

Once the pathogen is identified, antibiotics should be started or changed to empiric regimens for *M. abscessus*, mostly guided by in vitro susceptibilities. The most common regimens include a combination of macrolides (clarithromycin or azithromycin), aminoglycosides (amikacin), and cefoxitin. Azithromycin is generally the preferred macrolide used as it was thought to have lower rates of induction of ribosomal methylase, encoded by *erm(41)*, in *M. abscessus* than clarithromycin, though this has been called into question more recently. Meanwhile, with cefoxitin resistance, oxazolidinones like linezolid are considered empirically and have been used successfully in *M. abscessus* PD-associated infections, as there is moderate in vitro susceptibility, immunomodulation, clearance via multiple organs, and an oral formulation ideal for long term use.

The ideal duration of multidrug antibiotics in *M. abscessus* PD-associated infections is unknown, particularly in ESI. *M. abscessus* intrinsic antibiotic resistance and recurrence of infection after cessation of antibiotics necessitates urgent PD catheter removal. Recently, many case reports have described recurrence of *M. abscessus* ESI or extension into the PD tunnel track when PD catheter salvage or PD removal and reposition techniques were used instead of complete removal. The PD catheter removal date should then be considered the “start” date for these antibiotic regimens. In previously diagnosed *M. abscessus* ESI without tunnel or peritonitis involvement, treatment duration on multi-drug therapies has ranged from 6 to 28 weeks. Our patient was on a total of 3 weeks of azithromycin and 7 weeks of both linezolid and amikacin, with complete resolution of his infection.

Our case highlights an unusual cause of ESI in PD as well as some of the challenges associated in management, including catheter removal, antibiotic selection, and duration. Further research is needed to refine these challenges in the management of *M. abscessus* ESI, including risk factors for development of *M. abscessus*, optimal selection of empiric antibiotic therapies, duration of antibiotics, and PD catheter re-insertion timing.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Korey Bartolomeo https://orcid.org/0000-0003-0738-111X

Tushar J Vachharajani https://orcid.org/0000-0002-4494-966X

**Ethics Statement**

The authors have no financial or other conflicts of interest to report. Informed consent of the case report was waved as information was deidentified.

**References**

1. van Diepen ATN, Tomlinson GA and Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. *Clin J Am Soc Nephrol* 2012; 7(8): 1266–1271.

2. Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. *J Am Soc Nephrol* 2012; 23(8): 1398–1405.

3. Li PK-T, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. *Perit Dial Int* 2016; 36(5): 481–508.

4. Lee M-R, Sheng WH, Hung CC, et al. Mycobacterium abscessus complex infections in humans. *Emerg Infect Dis* 2015; 21(9): 1638–1646.

5. Song Y, Wu J, Yan H, et al. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. *Nephrol Dial Transplant* 2012; 27(4): 1639–1644.

6. Jheeta AS, Rangaiah J, Clark J, et al. Mycobacterium abscessus—an uncommon, but important cause of peritoneal dialysis-associated peritonitis–case report and literature review. *BMC Nephrol* 2020; 21(1): 491.

7. Slagle KM and Oblack DL. Mycobacterium abscessus peritonitis: a case report. *Clin Lab Sci* 1998; 11(4): 206–208.

8. Chamarthi G, Modi D, Andreoni K, et al. Simultaneous catheter removal and reinsertion, is it acceptable in *M. abscessus* exit site infection? *CEN Case Rep*. Epub ahead of print 16 March 2021. DOI: 10.1007/s13730-021-00593-y.

9. Marzuk SM, Rohit A, Nagarajan P, et al. An unusual case of unresolving tunnel infection in a patient on continuous ambulatory peritoneal dialysis. *Indian J Med Microbiol* 2018; 36: 600–602.

10. Jung JH and Ahn SH. Peritoneal dialysis catheter-related infection due to mycobacterium abscessus confused with rhodococcus. *J Korean Med Sci* 2020; 35(9): e44.

11. Richard M, Gutiérrez AV and Kremer L. Dissecting *erm(41)*-mediated macrolide-inducible resistance in mycobacterium abscessus. *Antimicrob Agents Chemother* 2020; 64(2): e01879–e01819.

12. Seki M, Kamioka Y, Takano K, et al. Mycobacterium abscessus associated peritonitis with CAPD successfully treated using a linezolid and tedizolid containing regimen suggested immunomodulatory effects. *Am J Case Rep* 2020; 21: e924642.

13. Hibi A, Kasugai T, Kamiya K, et al. Peritoneal dialysis-associated catheter infection caused by Mycobacterium abscessus in an elderly patient who was successfully treated with catheter removal. *CEN Case Rep* 2017; 6(2): 175–179.